Oxford Road
Manchester

M13 9WL

Macclesfield General Hospital

Manchester - North Manchester General Hospital

Manchester - Prestwich

Manchester - Wythenshawe

Tameside Hospital

0161 276 8736

Janice Wragg

0161 276 8021

Janice.Wragg@cmmc.nhs.uk

http://www.mint-research.org.uk

http://www.cmmc.nhs.uk/

Dr Mike L Picton, (Clinical Director), Dr Colin D Short, Dr Mike C Venning, Dr Alastair J Hutchison, Dr Faieza J Qasim, Dr Sandip Mitra, Dr Julian R Wright, Dr Anand Vardhan, Dr Mumtaz Patel, Dr Iren Szeki.
Associate Specialists - Dr Gill Hirst, Dr. Abdalla Bubtana

Janice Wragg, Dialysis Administrator MRI

Manchester Royal Infirmary is the centre of the East Sector Network, which provides nephrology services to North, South and Central Manchester, Tameside & Glossop, Stockport, South Trafford and South Cheshire PCTs (population 1.4 million), including North Manchester General, Wythenshawe, CMMC, Macclesfield, Stepping Hill, Tameside, Prestwich and The Christie hospitals. 'Outreach' renal clinics are held in each of these hospitals (except Christie) with sizeable maintenance haemodialysis units at MRI (120 patients), Wythenshawe (72 patients), NMGH (36 patients), Macclesfield (24 patients) and Prestwich (8 patients). In addition the Directorate manages around 130 PD patients, 50 home haemodialysis patients and 120 patients who have opted not to have dialysis (conservative management).

Within Central Manchester Trust, the Renal Directorate has close ties with the clinical disciplines of diabetes and vascular surgery, the Departments of Biochemistry, Immunology, Nuclear Medicine, Radiology and the University Medical School. It undertakes peritoneal and haemodialysis for the treatment of acute and chronic renal failure, and has an acute renal failure unit. It is a partner in the Regional Kidney/Pancreas Transplantation Unit, also based within Manchester Royal Infirmary, which performs around 180 renal transplants per year. In addition the Directorate provides renal support to the Regional Cardio-thoracic Transplant Unit at Wythenshawe Hospital. Home haemodialysis training is based at Wythenshawe Hospital (4 stations + dedicated staff).

In-patient care of renal patients for the Network is provided at MRI on Ward 26 (24 beds), Ward 22 (20 beds) and Ward 23 (7 beds + 3 acute dialysis beds). The Dialysis Unit comprises facilities for managing patients receiving haemodialysis (26 stations) in addition to out-patient peritoneal dialysis and CAPD training. The department manages over 100 acute renal failure patients per year. A new purpose-built renal unit opened in February 2007, containing a 30 station dialysis unit plus administrative offices and new research laboratories.

The Unit is actively involved in a variety of clinical and basic science research projects. Special interests within the Unit include peritoneal dialysis, metabolic bone disease, haemodialysis, diabetic nephropathy, glomerular disease, fibrosis and renal transplantation.

Recent publications include;

1. Worthington JE, McEwen A, McWilliam LJ, Picton ML, Martin S. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation. 2007;83(4):398-403.

2. Harris S, Coupes BM, Roberts SA, Roberts IS, Short CD, Brenchley PE. TGF-beta1 in chronic allograft nephropathy following renal transplantation. J Nephrol. 2007;20(2):177-85.

3. Ralph S, Brenchley PE, Summers A, Rosa DD, Swindell R, Jayson GC. Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. Cancer Sci. 2007;98(6):844-9.

4. Alachkar H, Qasim F, Ahmad Y, Helbert M. Meningococcal meningitis in a patient with urticarial vasculitis: is there a link? J Clin Pathol. 2007;60(10):1160-1.

5. Charlton-Menys V, Pisciotta L, Durrington PN, Neary R, Short CD, Calabresi L, Calandra S, Bertolini S. Molecular characterization of two patients with severe LCAT deficiency. Nephrol Dial Transplant. 2007;22(8):2379-82.

6. de Freitas D, Donne RL, Hutchison AJ. Lanthanum carbonate--a first line phosphate binder? Semin Dial. 2007;20(4):325-8.

7. Fargher EA, Eddy C, Newman W, Qasim F, Tricker K, Elliott RA, Payne K. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics. 2007;8(11):1511-9.

8. Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ. Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant. 2008;23(1):387-9.

9. Apostolou T, Hutchison AJ, Boulton AJ, Chak W, Vileikyte L, Uttley L, Gokal R. Quality of life in CAPD, transplant, and chronic renal failure patients with diabetes. Ren Fail. 2007;29(2):189-97.

10. de Freitas D, Jordaan A, Williams R, Alderdice J, Curwell J, Hurst H, Hutchison A, Brenchley PE, Augustine T, Summers AM. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int. 2008;28(3):271-6. [Jump to abstract]

11. Dilworth MR, Clancy MJ, Marshall D, Bravery CA, Brenchley PE, Ashton N. Development and functional capacity of transplanted rat metanephroi. Nephrol Dial Transplant. 2008;23(3):871-9. [Jump to abstract]

12. Harris LK, Baker PN, Brenchley PE, Aplin JD. Trophoblast-derived heparanase is not required for invasion. Placenta. 2008;29(4):332-7. [Jump to abstract]

13. Hutchison AJ, Laville M; on behalf of the SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant. 2008 Jun 24. [Jump to free full text]

14. D'souza Y, Short CD, McLeod D, Bonshek RE. Long-term follow-up of drusen-like lesions in patients with type II mesangiocapillary glomerulonephritis. Br J Ophthalmol. 2008;92(7):950-3. [Jump to abstract]

15. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA. Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment. Nephron Clin Pract. 2008;110(1):c15-c23. [Jump to free full text]

16. Hutchison AJ, Barnett ME, Krause R, J, Siami GA, On Behalf Of The Lanthanum Carbonate Study Group. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol. 2009 Mar;71(3):286-95.[Jump to abstract]

17. Hutchison AJ. Oral phosphate binders. Kidney Int. 2009 Mar 11. [Epub ahead of print][Jump to free full text]

18. Mohammed IA, Hutchison AJ. Oral phosphate binders for the management of serum phosphate levels in dialysis patients. J Ren Care. 2009 Mar;35 Suppl 1:65-70.[Jump to abstract]

19. Mohammed IA, Hutchison AJ. Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate. Ther Clin Risk Manag. 2008 Oct;4(5):887-93.[Jump to free full text]

20. Hutchison AJ. Lanthanum and phosphate: science, policy, and survival. Kidney Int. 2009 Feb;75(4):355-7.[Jump to free full text]

21. McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2009 Feb;4(2):401-9. Epub 2009 Jan 21.[Jump to abstract]

22. D'souza YB, Jones CJ, Short CD, Roberts IS, Bonshek RE. Oligosaccharide composition is similar in drusen and dense deposits in membranoproliferative glomerulonephritis type II. Kidney Int 2009 Apr;75(8):824-7. Epub 2009 Jan 28. [Jump to abstract]

23. Wright JR, Shurrab AE, Cooper A, Kalra PR, Foley RN, Kalra PA. Progression of cardiac dysfunction in patients with atherosclerotic renovascular disease. QJM 2009 Aug 10. [Epub ahead of print].[Jump to abstract]

24. Szeki I, Hutchison AJ. Lanthanum carbonate for hyperphosphatemia in patients with advanced CKD and patients receiving dialysis. Expert Rev Endocrinol Metabolism, 2009; 4 (vol 4):307-316. [Jump to abstract]

25. D'souza YB, Short CD. The eye - a window on the kidney. Nephrol Dial Transplant. 2009 Epub 2009 August 12. [Jump to free full text]

26. Wright JR, Hutchison AJ. Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag 2009;5:713-22. Epub 2009 Sep 7. [Jump to free full text]